XML 16 R2.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Current assets    
Cash and cash equivalents $ 47,920 $ 65,064
Short-term marketable securities (amortized cost of $174,186 and $281,122, respectively) 174,374 281,337
Accounts receivable, net 41,731 37,969
Inventory 8,440 14,448
Prepaid expenses and other current assets 11,287 11,370
Total current assets 283,752 410,188
Long-term assets    
Property and equipment, net 48,616 68,227
Operating lease right-of-use assets 45,767 52,096
Long-term marketable securities (amortized cost of $33,682) 33,660  
Restricted cash 2,897 2,932
Intangible assets, net 3,425 5,128
Goodwill 118,972 118,972
Other assets 2,287 3,591
Total assets 539,376 661,134
Current liabilities    
Accounts payable 7,265 7,719
Accrued liabilities 8,157 8,597
Accrued compensation and benefits 15,838 13,685
Current portion of operating lease liabilities 10,239 9,384
Current portion of deferred revenue 55,689 48,630
Current portion of revenue interest liability, net 865  
Total current liabilities 98,053 88,015
Long-term liabilities    
Operating lease liabilities, less current portion 79,148 89,388
Deferred revenue, less current portion 27,256 44,793
Revenue interest liability, net, less current portion 132,414 130,660
Other long-term liabilities 20  
Total liabilities 336,891 352,856
Commitments and contingencies (Note 12)
Shareholders’ equity    
Preferred stock: $0.0001 par value, 10,000,000 shares authorized at December 31, 2024 and 2023; no shares issued and outstanding at December 31, 2024 and 2023
Common stock: $0.0001 par value, 340,000,000 shares authorized at December 31, 2024 and 2023; 147,773,744 and 145,082,271 shares issued and outstanding at December 31, 2024 and 2023, respectively 14 14
Additional paid-in capital 1,506,353 1,452,502
Accumulated other comprehensive gain 166 215
Accumulated deficit (1,303,824) (1,144,332)
Total Adaptive Biotechnologies Corporation shareholders’ equity 202,709 308,399
Noncontrolling interest (224) (121)
Total shareholders’ equity 202,485 308,278
Total liabilities and shareholders’ equity $ 539,376 $ 661,134